SCHEMBL24784244

SCHEMBL24784244

COc1cnc(C)c(N2CCNCC2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 4/20 0.55
HTR3E A5X5Y0 2/20 0.55
HTR3B O95264 2/20 0.55
HTR3D Q70Z44 2/20 0.55
HTR3C Q8WXA8 2/20 0.55
CHRNB2 P17787 4/20 0.50
CHRNA4 P43681 4/20 0.50
ADRB1 P08588 3/20 0.50
NCF1 P14598 2/20 0.50
HTR6 P50406 3/20 0.49
HTR1A P08908 4/20 0.48
HTR7 P34969 3/20 0.48
HTR2B P41595 2/20 0.48
HTR1B P28222 1/20 0.48
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30047074 1.00 HTR3A (0.55) HTR3AHTR3EHTR3BHTR3DHTR3C
Hydrochloric Acid SCHEMBL29974181 0.98 HTR3A (0.54) HTR3AHTR3EHTR3BHTR3DHTR3C
Hydrochloric Acid SCHEMBL21626121 0.98 HTR3A (0.54) HTR3AHTR3EHTR3BHTR3DHTR3C
Hydrochloric Acid SCHEMBL23403785 0.98 HTR3A (0.54) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL24783779 0.83 DRD2 (0.42) HTR3AHTR1AHTR1BHTR2AHTR2C
SCHEMBL31510148 0.79 HTR3E (0.56) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL25124477 0.79 HRH3 (0.42) HTR6
SCHEMBL6348693 0.79 CHRNB2 (0.61) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL31378615 0.78 CHRNB2 (0.50) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL21646445 0.76 GPR6 (0.33) HTR3AHTR3EHTR3BHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 EP disclosed
CN-112672997-A Pyridazinone derivatives 大日本住友制药株式会社 2021-04-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 HTR3A 2895/4885HTR3E 2178/4885HTR3B 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.